I strive to do my best every day for the needs of my patients today and the hope of contributing to better treatments for the future.

EDUCATION

Undergraduate Degree

  • Colby College , 2001 , Waterville , ME

Medical School

  • Mayo Medical School , 2006 , Rochester , MN

Residency

Pediatrics
  • Boston Combined Residency Program (BCRP) , 2008 , Boston , MA

Residency

Pediatric Neurology
  • Boston Children's Hospital , 2011 , Boston , MA

Fellowship

Epilepsy; Clinical Neurophysiology
  • Boston Children’s Hospital , 2012 , Boston , MA

Fellowship

Neurogenetics; Epilepsy Genetics
  • Boston Children’s Hospital , 2013 , Boston , MA

Philosophy of Care

I am grateful for the values instilled in me through my medical education at the Mayo Clinic. These include their primary value “The needs of the patient come first” and logo of three interlocking shields representing a model of care based on integrated excellence in clinical practice, education and research.

Being a physician is a blessing and a privilege, and child neurology is a special field.  The resilience of children and families gives me strength.  I strive to do my best every day for the needs of my patients today and the hope of contributing to better treatments for the future. I am thankful to my patients, their families and my own, and excellent colleagues for all that they do to help me achieve my goals and your goals.

PROFESSIONAL HISTORY

After medical school training at Mayo Medical School, I did all of my post-graduate training in Boston then came on faculty at Boston Children’s Hospital.  My clinical focus in on Epilepsy and Neurogenetics/Epilepsy Genetics.  I see patients through a number of programs within Neurology including the fetal-neonatal neurology program with a focus towards neurogenetic disorders and epilepsy.  Additionally I see patients along with colleagues Dr. Benson and Dr. Gorman in our joint Inflammatory Epilepsy Program. I am a clinician and clinical researcher.  My research is in the field of Epilepsy Genetics, particularly genetics of early onset epileptic encephalopathies and infantile spasms.  Additionally, I am working towards a master of science degree in Epidemiology through the Harvard T.H. Chan School of Public Health, with a focus on Genetic Epidemiology.

Dr. Olson serves as an expert for the Department of Neurology for Boston Children's Hospital Precision Medicine Service. For more information about the Precision Medicine Service please visit bostonchildrens.org/precisionmed.

CERTIFICATIONS

  • American Board of Psychiatry and Neurology, Child and Adolescent Neurology
  • American Board of Psychiatry and Neurology, Epilepsy

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Characterization of the GABRB2-Associated Neurodevelopmental Disorders. Ann Neurol. 2021 Mar; 89(3):573-586. View abstract
  2. Modelling and treating GRIN2A developmental and epileptic encephalopathy in mice. Brain. 2020 07 01; 143(7):2039-2057. View abstract
  3. Biological concepts in human sodium channel epilepsies and their relevance in clinical practice. Epilepsia. 2020 03; 61(3):387-399. View abstract
  4. Genetic diagnoses in epilepsy: The impact of dynamic exome analysis in a pediatric cohort. Epilepsia. 2020 02; 61(2):249-258. View abstract
  5. CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development. Epilepsia. 2019 08; 60(8):1733-1742. View abstract
  6. Severity Assessment in CDKL5 Deficiency Disorder. Pediatr Neurol. 2019 08; 97:38-42. View abstract
  7. PLPHP deficiency: clinical, genetic, biochemical, and mechanistic insights. Brain. 2019 03 01; 142(3):542-559. View abstract
  8. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review. Pediatr Neurol. 2019 08; 97:18-25. View abstract
  9. Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder. Epilepsy Res. 2019 03; 151:31-39. View abstract
  10. Spectrum of neurodevelopmental disease associated with the GNAO1 guanosine triphosphate-binding region. Epilepsia. 2019 03; 60(3):406-418. View abstract
  11. A Recurrent De Novo PACS2 Heterozygous Missense Variant Causes Neonatal-Onset Developmental Epileptic Encephalopathy, Facial Dysmorphism, and Cerebellar Dysgenesis. Am J Hum Genet. 2018 10 04; 103(4):631. View abstract
  12. Clinical and Functional Characterization of the Recurrent TUBA1A p.(Arg2His) Mutation. Brain Sci. 2018 Aug 07; 8(8). View abstract
  13. A Recurrent De Novo PACS2 Heterozygous Missense Variant Causes Neonatal-Onset Developmental Epileptic Encephalopathy, Facial Dysmorphism, and Cerebellar Dysgenesis. Am J Hum Genet. 2018 05 03; 102(5):995-1007. View abstract
  14. Neonatal epilepsy genetics. Semin Fetal Neonatal Med. 2018 06; 23(3):197-203. View abstract
  15. Should patients with complex febrile seizure be admitted for further management? Am J Emerg Med. 2018 08; 36(8):1386-1390. View abstract
  16. Characterization of a novel variant in siblings with Asparagine Synthetase Deficiency. Mol Genet Metab. 2018 03; 123(3):317-325. View abstract
  17. Imaging features and prognostic factors in fetal and postnatal torcular dural sinus malformations, part I: review of experience at Boston Children's Hospital. J Neurointerv Surg. 2018 May; 10(5):467-470. View abstract
  18. Imaging features and prognostic factors in fetal and postnatal torcular dural sinus malformations, part II: synthesis of the literature and patient management. J Neurointerv Surg. 2018 May; 10(5):471-475. View abstract
  19. A randomized controlled trial of levodopa in patients with Angelman syndrome. . 2018 05; 176(5):1099-1107. View abstract
  20. Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: Experience of >100 patients. Epilepsia. 2017 08; 58(8):1415-1422. View abstract
  21. Genetics and genotype-phenotype correlations in early onset epileptic encephalopathy with burst suppression. Ann Neurol. 2017 Mar; 81(3):419-429. View abstract
  22. A Model Program for Translational Medicine in Epilepsy Genetics. J Child Neurol. 2017 03; 32(4):429-436. View abstract
  23. BRAT1 mutations present with a spectrum of clinical severity. . 2016 09; 170(9):2265-73. View abstract
  24. Pediatric anti-Hu-associated encephalitis with clinical features of Rasmussen encephalitis. Neurol Neuroimmunol Neuroinflamm. 2015 Oct; 2(5):e150. View abstract
  25. SCN2A encephalopathy: A major cause of epilepsy of infancy with migrating focal seizures. Neurology. 2015 Sep 15; 85(11):958-66. View abstract
  26. The genetics of the epilepsies. Curr Neurol Neurosci Rep. 2015 Jul; 15(7):39. View abstract
  27. Mutations in epilepsy and intellectual disability genes in patients with features of Rett syndrome. . 2015 Sep; 167A(9):2017-25. View abstract
  28. Evaluation and treatment of autoimmune neurologic disorders in the pediatric intensive care unit. Semin Pediatr Neurol. 2014 Dec; 21(4):284-90. View abstract
  29. Genetic forms of epilepsies and other paroxysmal disorders. Semin Neurol. 2014 Jul; 34(3):266-79. View abstract
  30. Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience. Epilepsia. 2014 Aug; 55(8):1235-44. View abstract
  31. E-066 pathogenesis of dural sinus malformations as demonstrated by fetal imaging: a decision-making crucible for parents and clinicians. J Neurointerv Surg. 2014 Jul; 6 Suppl 1:A69-70. View abstract
  32. Copy number variation plays an important role in clinical epilepsy. Ann Neurol. 2014 Jun; 75(6):943-58. View abstract
  33. Clinical application and evaluation of the Bien diagnostic criteria for Rasmussen encephalitis. Epilepsia. 2013 Oct; 54(10):1753-60. View abstract
  34. Micro-duplications of 1q32.1 associated with neurodevelopmental delay. Eur J Med Genet. 2012 Feb; 55(2):145-50. View abstract
  35. Febrile infection-related epilepsy syndrome (FIRES): does duration of anesthesia affect outcome? Epilepsia. 2011 Oct; 52 Suppl 8:28-30. View abstract
  36. Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. Epilepsia. 2011 Nov; 52(11):1956-65. View abstract
  37. Rufinamide for the treatment of epileptic spasms. Epilepsy Behav. 2011 Feb; 20(2):344-8. View abstract
  38. Neural stem cell- and Schwann cell-loaded biodegradable polymer scaffolds support axonal regeneration in the transected spinal cord. Tissue Eng Part A. 2009 Jul; 15(7):1797-805. View abstract